Please provide your email address to receive an email when new articles are posted on . Adults with isolated distal deep vein thrombosis experience fewer short- and long-term adverse outcomes compared ...

Deep vein thrombosis (DVT) occurs when a blood clot forms in a large (deep) vein. Proximal DVTs occur in deep veins above the knee and isolated, distal DVTs can occur when smaller blood clots form in ...

If the choice is made to anticoagulate patients with symptomatic isolated distal deep vein thrombosis (DVT), outcomes will be improved with 12 versus 6 weeks of treatment, the randomized, ...

Twelve months of edoxaban is superior to three months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis (DVT), according to late breaking research ...

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after ...

Amsterdam, Netherlands – 28 Aug 2023: Twelve months of edoxaban is superior to three months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis (DVT), ...

Effect of a Community Health Worker–Led Intervention Among Low-Income and Minoritized Patients With Cancer: A Randomized Clinical Trial More than 90% of patients in each group were treated with ...

Please provide your email address to receive an email when new articles are posted on . Longer vs. shorter-duration anticoagulation reduces thrombotic event risk for patients with cancer and isolated ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window AMSTERDAM -- A ...

Patients with active cancer and newly diagnosed isolated distal deep vein thrombosis (DVT) who received 12 months of edoxaban (Savaysa) had fewer thrombotic events at 1 year than those who received 3 ...